Robert Hervé

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Symptomatic Treatment With Lanreotide Microparticles in Inoperable Bowel Obstruction Resulting From Peritoneal Carcinomatosis: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Pascale Mariani, Joëlle Blumberg, Alain Landau et al. · Journal of Clinical Oncology · 2012 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer

Félix Blanc‐Durand, Roseline Tang, Margaux Pommier et al. · Clinical Cancer Research · 2023 · 42 citations

Medicine, Molecular Genetics, Oncology +17

Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first‐line therapy for triple‐negative, metastatic, or locally advanced breast cancer: Results from the GINECO A‐TaXel phase 2 study

Jean‐Marc Ferrero, Anne‐Claire Hardy‐Bessard, Olivier Capitain et al. · Cancer · 2016 · 35 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Coumarin‐induced skin necrosis associated with acquired protein s deficiency and antiphospholipid antibody syndrome

Marie‐José Wattiaux, Robert Hervé, Annie Robert et al. · Arthritis & Rheumatism · 1994 · 33 citations

Medicine, Dermatology, Immunology +11